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ABSTRACT 
Purpose:  
The proliferation of gene-panel testing precipitates the need for a breast cancer (BC) risk model that 
incorporates the effects of mutations in several genes and family history (FH). We extended the 
BOADICEA model to incorporate the effects of truncating variants in PALB2, CHEK2 and ATM. 
Methods: 
The BC incidence was modelled via the explicit effects of truncating variants in BRCA1/2, PALB2, 
CHEK2 and ATM and other unobserved genetic effects using segregation analysis methods. 
Results: 
The predicted average BC risk by age 80 for an ATM mutation carrier is 28%, 30% for CHEK2, 50% for 
PALB2, 74% for BRCA1 and BRCA2. However, the BC risks are predicted to increase with FH-burden.  
In families with mutations, predicted risks for mutation-negative members depend on both FH and 
the specific mutation. The reduction in BC risk after negative predictive-testing is greatest when a 
BRCA1 mutation is identified in the family, but for women whose relatives carry a CHEK2 or ATM 
mutation, the risks decrease slightly. 
Conclusions:  
The model may be a valuable tool for counselling women who have undergone gene-panel testing 
for providing consistent risks and harmonizing their clinical management. A web-application can be 
used to obtain BC- risks in clinical practice (http://ccge.medschl.cam.ac.uk/boadicea/). 
 
Keywords: breast cancer; risk prediction; BOADICEA; BRCA1; BRCA2; PALB2; CHEK2; ATM; user 
interface; gene-panel 
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INTRODUCTION  
Breast cancer exhibits strong familial aggregation, such that the risk of the disease increases with 
increasing number of affected relatives. First degree relatives of women diagnosed with breast 
cancer are at approximately 2 times greater risk of developing breast cancer themselves than 
women from the general population1. Many breast cancer susceptibility variants have been 
identified to date. Approximately 15-20% of this excess familial risk is explained by rare, high 
penetrance mutations in BRCA1 and BRCA22,3. Other rare, intermediate risk variants (e.g. mutations 
in PALB2, CHEK2 and ATM) are estimated to account for ~5% of the breast cancer familial 
aggregation4-6, and the common, low-risk alleles identified through genome-wide association studies 
to account for a further 14% of the familial risk7,8.  
To provide comprehensive genetic counselling for breast cancer, it is important to have risk 
prediction models that take into account the effects of all the known breast cancer susceptibility 
variants, and also account for the residual familial aggregation of the disease. Some existing genetic 
risk prediction algorithms incorporate the explicit effects of BRCA1 and BRCA2 mutations, including 
BRCAPRO9, IBIS10 and BOADICEA3,11. BOADICEA accounts for the residual familial aggregation of 
breast cancer in terms of a polygenic component that models the multiplicative effects of a large 
number of variants each making a small contribution to the familial risk3.  
Next generation sequencing technologies that enable the simultaneous sequencing of multiple 
genes through gene-panels12,13 have now entered clinical practice. However, the clinical utility of 
results from such genetic testing remains limited as none of the currently available risk prediction 
models incorporate the simultaneous effects of the rare-intermediate risk variants and other breast 
cancer risk factors, in particular explicit family history. As a result, providing risk estimates for 
women who carry these mutations, and their relatives, is problematic6.  
In this paper, we describe an extension to the BOADICEA model to incorporate the effects of 
intermediate risk variants for breast cancer, specifically loss of function mutations in the three genes 
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for which the evidence for association is clearest and the risk estimates most precise: PALB2, CHEK2 
and ATM. The resulting model allows for consistent breast cancer risk prediction in unaffected 
women on the basis of their genetic testing results and their family history.  
MATERIALS AND METHODS 
Breast Cancer Incidence in BOADICEA 
We build on the existing BOADICEA model2,3,11. Briefly, in this model, the breast cancer incidence, 
 ti , for individual i  at age t is assumed to be birth cohort specific, and to depend on the 
underlying BRCA1 and BRCA2 genotypes and the polygenotype through a model of the form: 
           tPGGtGttt iiiii  212110 1exp  ,                                                         Equation(1) 
where  t0  is the baseline incidence for the cohort, iG1 is an indicator variable taking values 1 if a 
BRCA1 mutation is present and 0 otherwise, and similarly iG2 for BRCA2.  t1  and  t2  represent 
the age-specific log-relative risks associated with BRCA1 and BRCA2 mutations respectively, relative 
to the baseline incidence (applicable to a non-mutation carrier with a zero polygenic component) 
and where  tPi  is the polygenic effect, assumed to be normally distributed with mean 0 and 
variance  tP
2 . 
The effects of mutations in BRCA1 and BRCA2 are modelled through a single locus “major gene” with 
three alleles (BRCA1, BRCA2 and wild-type). The BRCA1 and BRCA2 alleles are assumed to be 
dominantly inherited14. As a further simplification, carriers of both the BRCA1 and BRCA2 alleles are 
assumed to be susceptible to BRCA1 risks. These simplifications reduce the number of possible 
“major” genotypes from 9 to 3: (1) being a BRCA1 mutation carrier; (2) being a BRCA2 mutation 
carrier; and (3) being a non-mutation carrier.  
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The BOADICEA genetic model uses the Elston-Stewart peeling algorithm to compute the pedigree 
likelihood15,16. As a result, the number of computations increases exponentially with the number of 
possible genotypes in the model. To maintain computational efficiency, we incorporated the effects 
of risk-conferring variants in PALB2, CHEK2 and ATM into the model by introducing an additional 
allele for each gene (representing a mutation in that gene) to the BRCA1/2 major gene locus, 
resulting in a locus with 6 alleles. In comparison with a model that has a single locus for each gene, 
this approximation can be justified by the low allele mutation frequencies for all genes (Table 1), 
because the probability of carrying mutations in more than one of these genes is low17, relative to 
the probability of carrying one or no mutation. Currently, few published data describe the cancer 
risks to individuals carrying more than one mutation18. Here we have assumed that the risks follow a 
dominant model, with the order of precedence being BRCA1, BRCA2, PALB2, CHEK2, ATM and wild-
type. Under this model, in the presence of a mutation in one gene, no additional risk is conferred by 
a second mutation in another gene lower in the dominance chain.  
Relative Risks for Female Breast Cancer 
We extended the model for the breast cancer incidence to incorporate the effects of rare variants in 
PALB2, CHEK2 and ATM, such that: 
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 tPtGtGttt Riiii ,                                                       Equation(2) 
where  0 ,  t1 , iG1 ,  t2  and iG2  are as described in Equation(1), and  iG3 , iG4 , and iG5 , are 
indicator variables taking values 1 if a mutation is present and 0 otherwise, for PALB2, CHEK2 and 
ATM respectively.  t3 ,  t4  and  t5  represent the age-specific log-relative risks associated 
with PALB2, CHEK2 and ATM mutations respectively, relative to the baseline incidence (applicable to 
a non-mutation carrier with a zero polygenic component).  tPRi  is the residual polygenic 
component, with mean 0, and variance  tR
2 , explained below. 
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To implement the model, we assumed the mutation frequencies and relative risks (RRs) summarised 
in Table 1. The RR estimates (Table 1) represent estimates relative to the population incidences and 
are therefore RR over all polygenic effects. Multiplying the RRs (Table 1) by the cohort and age 
specific incidences yields the average incidences in carriers of PALB2, CHEK2 and ATM mutations 
over all polygenic effects. To obtain  t3 ,  t4  and  t5 , we constrained the overall incidences 
(using as weights the major genotype and polygenic frequencies)  to agree with the population 
breast cancer incidence, for each birth cohort separately. This process is described in detail 
elsewhere14 
To ensure that the familial risks predicted by this extended model remain consistent with the 
previous model, we adjusted the variance of the polygenic component to account for the fact that 
the contributions of PALB2, CHEK2 and ATM to the genetic variance are now explicitly accounted for 
in the major gene, following the process described in19. Briefly, the total polygenic variance ( 2P ) 
was decomposed into the sum of the known variance ( 2K ), due to the three variants, and residual 
variance ( 2R ),  
222
RKP   , 
The known variance, 2K , can be calculated as a function of the joint RRs and mutation frequencies 
of the three risk variants19. This assumes that the effect of each variant and the effect of residual 
polygene (which describes residual familial aggregation) are multiplicative. This is in line with recent 
findings for PALB2 mutations20. This model is also consistent with the higher RR for CHEK2 1100delC 
for breast cancer based on familial cases21,22, the higher RR for bilateral breast cancer23, and  the 
increased risk of breast cancer in relatives of breast cancer patients who are CHEK2 carriers24. A 
higher RR for familial breast cancer for ATM carriers has also been found, though the data are more 
limited for ATM25. 
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PALB2 Characteristics 
As there are very limited data from case-control studies for PALB2 or ATM, we used alternative 
family-based data. Age dependent RRs of female breast cancer for carriers of loss of function 
variants in PALB2 were taken from a large collaborative family-based study20. With the exception of 
specific Nordic founder mutations, data on mutation frequencies in the general population are 
sparse. We assumed a mutation allele frequency of 0.057% (or a mutation frequency of ~0.11% 
(10/8705)) based on data from targeted sequencing of 8705 controls from the UK (unpublished 
data). This is close to the average estimate across published estimates26. 
CHEK2 Characteristics 
Most existing data describe the CHEK2 1100delC variant, which is the most common truncating 
variant in northern European populations27. CHEK2 1100delC has been evaluated in many case-
control studies22,28. As a result, we based the CHEK2 estimates on the CHEK2 1100delC carrier 
estimates from a meta-analysis28. We assumed that the allele frequency of the 1100delC mutations 
was 0.26%, the combined frequency across unselected population controls of European ancestry28. 
The missense variant CHEK2 I157T has also been shown to confer increased risks of breast cancer7,29. 
However, these risks are much lower than those conferred by CHEK2 1100delC, and are closer to 
those conferred by common susceptibility variants. Consequently, CHEK2 I157T has been included in 
published Polygenic Risk Scores with other common-low penetrance alleles, and it will be included in 
future model extensions30. 
There is some evidence that the RRs for breast cancer in CHEK2 1100delC carriers decline with age22. 
However, since age-specific estimates are currently imprecise, we used a single RR estimate across 
all ages. 
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ATM Characteristics 
We obtained estimates for truncating mutations in ATM from a combined analysis of three 
estimates from cohort studies of relatives of Ataxia-Telangiectasia (A-T) patients (Table 1)6. The large 
majority of A-T patients carry two truncating ATM mutations, and relatives of A-T patients are 
therefore known to have a high probability of being carriers of an ATM mutation. We assumed that 
the allele frequency of truncating variants in ATM was 0.19% based on data from UK controls25. As 
for CHEK2, there is some evidence of a decline in RR with age31, but in the absence of relative age-
specific estimates, we used a single estimate across all ages. 
Relative Risks for Other Cancers 
In addition to the risks of female breast cancer, BOADICEA takes into account the associations of 
BRCA1 and BRCA2 mutations with the risks of male breast cancer, ovarian cancer, male and female 
pancreatic cancer, and prostate cancer3. Several studies have investigated the associations of the 
truncating variants in PALB2, ATM and CHEK2 1100delC with the risks of these cancers (and 
others)20,29,31,32. However, none of the studies have provided convincing evidence of association for 
any of these cancers, and accurate penetrance estimates are currently lacking for those cancers that 
may have associations. Therefore, for the purpose of the current implementation, we assumed that 
these mutations are not associated with elevated risks of other cancers.  
Incorporating Breast Tumour Pathology Characteristics 
Previous studies2,11 describe the incorporation into BOADICEA of differences in tumour pathology 
subtypes between BRCA1, BRCA2 and non-carrier breast cancers. Specifically, BOADICEA includes 
information on tumour oestrogen receptor (ER) status, triple negative (oestrogen, progesterone and 
HER2 negative) (TN) status, and the expression of the basal cytokeratin markers CK5/6 and CK14.  
Breast cancers in CHEK2 1100delC mutation carriers have been found to be ER-positive, at a greater 
proportion compared to tumours in non-CHEK2 mutation carriers (ER-positive tumours in CHEK2 
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1100delC carriers=88% (290/331) vs 78% in general population)33. Reliable data pertaining to the TN 
and basal cytokeratin receptor status are not currently available. Therefore, in the current 
implementation, we only incorporated differences by breast cancer ER-status for CHEK2 1100delC 
carriers, assuming that 88% of tumours in carriers are ER-positive. Age specific distributions were 
not available. 
 Published data on the prevalence of these tumour subtypes in PALB2 associated breast cancers are 
currently sparse, and although some differences compared to the general population have been 
reported, these are based on small numbers20,34. Currently there are no available data pertaining to 
tumour pathology subtype distributions for carriers of ATM truncating mutations. We therefore 
assumed that the tumour subtype distributions for PALB2 and ATM mutation carriers are the same 
as in the general population. 
Mutation Screening Sensitivity 
We have introduced separate mutation test screening sensitivities for PALB2, CHEK2 and ATM to 
allow for the fact that some risk-conferring variants in these genes may be missed by current 
screening methods. In the BOADICEA Web Application (BWA), we assumed default values of 90% for 
PALB2 and ATM truncating variants, and 100% for the CHEK2 1100delC variant. However, these 
values can be customised by users, where appropriate. The specificity of mutation testing was 
assumed to be 100%.  
RESULTS 
Fig 1(a) (and Fig S1) shows the implied average cumulative breast cancer risks predicted by 
BOADICEA by mutation status, on the basis of the assumed RR parameters for an unaffected female 
aged 20 born in 1975. The predicted average breast risk by age 80 for a CHEK2 mutation carrier was 
29.9%, 28.2% for ATM, 50.1% for PALB2, 73.5% for BRCA1 and 73.8% for BRCA2.  
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On the basis of the assumed mutation frequencies and RRs and modelling assumptions, the known 
polygenic variance (  tK
2 ) due to the effects of PALB2, CHEK2 and ATM are given in Table 2. The 
age dependence of the variances due to PALB2, CHEK2 and ATM is a consequence of the fact that 
relative risks vary with age (in particular for PALB2) and the age dependence of the frequency of 
mutation carriers among the unaffected population, which decreases with age (elimination effect).    
The proportion of polygenic variance accounted for by the three genes varied from 3.0% at age 25 to 
9.8% at age 75.  
Mutation Carrier Probabilities 
Fig 2 shows the mutation carrier probabilities predicted by BOADICEA for each gene, for (a) a female 
with unknown family history as a function of her age of cancer diagnosis, and (b) for a 30 year old 
female diagnosed with breast cancer, whose mother has had breast cancer, as a function of her 
mother’s age at diagnosis (also given in Tables S1 and S2). The mutation carrier probabilities for ATM 
and CHEK2 did not show a marked change with age at diagnosis (reflecting the assumption of a 
constant RR by age), but the mutation carrier probabilities decreased with age for PALB2, though 
less markedly than for BRCA1 or BRCA2. As expected, the mutation carrier probabilities were higher 
for women with a family history, but the effect was more marked for BRCA1, BRCA2 and PALB2 than 
for CHEK2 or ATM.  
Predicted Cancer Risks for Mutation Carriers are Family History Specific 
In our model, the residual polygenic component was assumed to act multiplicatively with PALB2, 
CHEK2 and ATM mutations on the risk of developing breast cancer. As a result, the breast cancer 
risks for mutation carriers will vary by family history of breast cancer. Fig 1 shows the predicted 
cumulative breast cancer risk for a 20 year old UK woman born in 1975 by her mutation status. In (a) 
the woman was assumed to have unknown family history; in (b) to have a mother affected with 
breast cancer at age 40; and in (c) to have a mother and sister who are cancer free at ages 70 and 50 
respectively. The figures show clearly that the predicted breast cancer risks increased with 
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increasing number of affected relatives, and depend on the phenotypes of the unaffected family 
members. For example, although the average breast cancer risks by age 80 for CHEK2 and ATM 
mutation carriers were lower than 30% (a common criterion for “high” risk, used for example in the 
NICE guideline35) the breast cancer risk exceeded this threshold when a mutation carrier had a family 
history of breast cancer (e.g. 42.6% for an ATM and 44.7% for CHEK2 mutation carrier with an 
affected mother).  Comparing Figures 1 (c) and 1 (a) we see that the risk for a woman with no history 
of breast cancer is lower than the average breast cancer risk. 
The Effect of Negative Predictive Testing 
The extended BOADICEA model can also be used to calculate the predicted risks in families in which 
mutations are identified, but other family members test negative for the mutation. This is 
demonstrated for a number of family history scenarios in Fig 3, which each depend on the mutation 
status of the proband and her mother. The predicted risks for mutation negative family members 
depend on both the family history of breast cancer and the specific mutation identified in the family. 
Thus for families with a history of breast cancer, namely (c), (e) and (g), the reduction in breast 
cancer risk after negative predictive testing is greatest when a BRCA1 mutation was identified in the 
family, with the risks being close to (though still somewhat greater than) the correspond risks based 
on population rates. This effect was most noticeable for women with a strong family history. The 
reduction in risk in women whose mother carried a BRCA2 or PALB2 mutation is less marked, while 
for women whose mother carried a CHEK2 or an ATM mutation, the risks decreased only slightly 
with a negative predictive test, even for women with a strong family history. For a woman with no 
history of breast cancer(Figure 3 (a)), her risk on the basis of family history alone (i.e. in an untested 
family)  was slightly lower than the population risk. After negative predictive testing her predicted 
risk decreased further. The biggest decrease was observed when a BRCA1 mutation was identified in 
the mother. 
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Updates to the BOADICEA Web Application 
We have now updated the BWA (http://ccge.medschl.cam.ac.uk/boadicea/) to accommodate the 
extensions to the BOADICEA model presented here. The BWA enables users to either build a 
pedigree online for processing, or to upload a text file containing one or more pedigrees for 
processing. When users build an input pedigree online, the program now enables users to specify 
PALB2, CHEK2 and ATM genetic test results in risk calculations. Similarly, we have extended the 
BOADICEA import/export format (described in Appendix A of the BWA v4 user guide: 
https://pluto.srl.cam.ac.uk/bd4/v4/docs/BWA_v4_user_guide.pdf) so that users can include this 
information in the text files that they upload for processing. 
DISCUSSION 
Cost-effective sequencing technologies have brought multi-gene panel testing into mainstream 
clinical care6,13,36. Although several established breast cancer susceptibility genes are included in 
these panels, their clinical utility is limited by the lack of risk prediction models that consider the 
effects of mutations in these genes and other risk factors for breast cancer, in particular family 
history. Here, we present an extended BOADICEA model that incorporates the effects of rare protein 
truncating variants in PALB2, CHEK2 and ATM. This is the first breast cancer risk prediction model to 
include the explicit effects of breast cancer susceptibility genes other than BRCA1 and BRCA2, and it 
can be used to provide comprehensive risk counselling on the basis of family history and mutation 
screening in the five genes. The model can also be used to predict future risks of developing breast 
cancer and the likelihood of carrying truncating mutations in any of the five genes.  
The extended BOADICEA model is based on a number of assumptions. To ensure the model is 
computationally efficient we used a single "major" locus with six alleles representing the truncating 
variants in the five genes and a wild-type allele.  In comparison with a genetic model consisting of 5 
separate loci each with 2 alleles, this should be a reasonable approximation as all the variants are 
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rare. Algebraically leading errors should be proportional to the product of any two allele 
frequencies, which is of the order of 610 . Our empirical measurements confirm that this is the case, 
with leading differences in the 6th significant figure. However, it is possible the errors will be greater 
in families segregating more than one rare variant. It also represents a substantial reduction in the 
number of genotypes (36 V’s 1024), and hence in execution time; we measure execution time to be 
reduced by a factor of 21000. These simplifications will become more critical as the number of 
susceptibility genes included in the model increases. A previous study6 identified six other genes for 
which the association with breast cancer was well established (TP53, PTEN, STK11, CDH1, NF1 and 
NBN), and this list is likely to increase as large exome- and targeted- sequencing studies are 
completed. 
In the absence of robust data on the risks conferred by carriers of 2 or more truncating variants (in 
different genes), we assumed that dual mutation carriers develop breast cancer according to 
incidences for the higher penetrance gene. Recent evidence suggests that gene-gene interaction 
between CHEK2, ATM, BRCA1 and BRCA2 may not be multiplicative (indeed a multiplicative model 
would clearly be implausible for BRCA1 and BRCA2, since it would predict an extremely high risk to 
double mutation carriers at very young ages)18. This may reflect the biological relationships between 
the proteins encoded by the genes. The proteins encoded by all five genes play roles in DNA repair, 
and loss of function mutations in these genes are predicted to impair DNA repair. Our 
implementation would be consistent with a model where if the pathway is disrupted by one 
mutation, further disruption by a lower penetrance mutation would not lead to an increased risk.  
Although there is strong evidence that mutations in PALB2, CHEK2 and ATM confer increased risk of 
breast cancer in females6, there are currently no precise risk estimates for the other cancers 
considered by BOADICEA (male breast, ovarian, pancreatic or prostate), or indeed other cancers. 
However, several studies have provided tentative evidence of associations20,32. Due to the lack of 
precise cancer risk estimates, we have assumed no association between truncating variants in 
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PALB2, CHEK2 and ATM (i.e. RR=1). If there are true associations between the PALB2, CHEK2 and 
ATM truncating variants and other cancer risks, we expect that PALB2, CHEK2 and ATM mutation 
carrier probabilities may potentially be underestimated in families where other cancers occur. 
However, our implementation is flexible enough that should accurate risk estimates for other 
cancers become available, they can easily be included. 
BOADICEA allows data on cancer tumour characteristics to be taken into account, as we have done 
previously for BRCA1 and BRCA22,11,37. The provision of subtype-specific risks can be useful for 
genetic counselling and may guide chemoprevention. However, data on the additional genes are 
currently sparse. In this model, we incorporated a higher probability of ER-positive tumours in 
CHEK2 1100delC carriers, relative to non-carriers33. Some studies have suggested differences in the 
characteristics of tumours from PALB2 mutation carriers and non-carriers, but larger studies will be 
required to establish such differences20,34.  
In this model, we considered only the effects of truncating variants in PALB2, ATM and of  the CHEK2 
1100delC variant, for which reasonably robust breast cancer risk estimates are available. In doing 
this, we are making the usual simplification that all truncating variants in these genes confer similar 
risks. While there is no evidence to contradict this, it may change as further data accumulate. In 
addition, there is evidence that missense variants in both CHEK2 and ATM also confer elevated 
breast cancer risks, but that the risks that they confer can differ from the risks associated with 
truncating variants. For example, the ATM c.7271T>G missense variant has been reported to confer 
a higher risk than truncating variants, but the confidence intervals associated with this estimate are 
currently wide38. It has been suggested that other rare, evolutionarily unlikely missense variants in 
ATM are also associated with increased breast cancer risks39. Future extensions of BOADICEA can 
accommodate such differences on the basis of more precise cancer risk estimates. In CHEK2, the 
missense variant Ile157Thr has been associated with a lower risk than the 1100delC variant40. This 
variant has been recently incorporated into a polygenic risk score on the basis of common genetic 
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variants30 and we expect to incorporate this into BOADICEA through ongoing extensions that will 
include the effects of common genetic variants. The model could also be applicable for other 
truncating variants in CHEK2 , under the assumption that they confer similar risks to the 1100delC 
variant. However, the available data are scarce and some modification of the mutation frequencies 
may be required.  
Under the BOADICEA model, women   testing   negative   for   known familial mutations (true 
negatives) and who have family history of breast cancer are predicted to be at higher risk of breast 
cancer  than the general population. The level of risk depends on both family history and the specific 
mutation identified in the family.  So far, epidemiological studies have reported estimates for “true 
negatives” only in the context of families with BRCA1 and BRCA2 mutations41-46 but the estimated 
relative risks (compared to the population risks) have been found to vary widely. Moreover, all the 
reported estimates are associated with wide confidence intervals because the studies have been 
based on small sample sizes. The reported estimates are summarised in Table S3.To provide a direct 
comparison with the predicted risks by BOADICEA we have also  included the implied relative risks 
for the “true negative” women in Figure 3 relative to the population risk in Table S3. These are all in 
line with the published estimates for true negatives. Therefore, the predictions by BOADICEA are 
consistent with published epidemiological data.  It is worth noting that if the true relative risks for 
the “true negatives” in families with BRCA1 and BRCA2 mutations are in line with those predicted by 
BOADICEA, very large prospective studies of “true negatives” will be necessary to demonstrate 
significant associations.  
 
The current model is a synthetic model, based on segregation analyses of families in the UK together 
with risk estimates derived from studies of European populations. We have previously implemented 
procedures for extrapolating the model to populations with different baseline incidence rates, on 
the assumption that the RRs conferred by the genetic variants in the model are independent of the 
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population11. Thus, the model should be broadly applicable to developed populations of European 
ancestry, but its applicability to populations with lower incidence rates, and populations of non-
European ancestry, has yet to be evaluated. The implementation also allows the allele frequencies to 
be adjusted. This may be particularly relevant for CHEK2; in European populations the founder 
1100delC variant accounts for the majority of carriers of truncating variants, and its frequency varies 
widely across populations.  
The extended BOADICEA model presented here has addressed a major gap in breast cancer risk 
prediction, by including the effects of truncating variants in PALB2, CHEK2 and ATM that are included 
in widely used commercial gene-panels. The model could be a valuable tool in the counselling 
process of women who have undergone gene-panel testing for providing consistent breast cancer 
risks and thus harmonizing the clinical management of at risk individuals. Future studies should aim 
to validate this model in large prospective cohorts with mutation screening information and to 
evaluate the impact of the risk predictions on decision making.
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TABLE AND FIGURE LEGENDS: 
Table 1. Mutation frequency and relative risks (RR) for loss of function variants in PALB2, CHEK2 and 
ATM. The RRs for PALB2 are taken from20. The mutation frequency for PALB2 is taken from a private 
communication from Easton and Pharaoh based on data from unaffected individuals from the UK. 
Relative risks for CHEK2 and ATM are taken from6. The allele frequency for CHEK2 is taken from28, 
and the allele frequency for ATM is taken from31. 
 
Table 2. The variance explained by PALB2, CHEK2 and ATM and the percentage of the overall 
polygenic variance explained by all three combined. 
 
Figure 1. BOADICEA Breast Cancer Risk by Mutation Status and Family History. BOADICEA risk by 
mutation status for a female in the UK age 20 born in 1975: (a) with unknown family history (i.e. for 
the average female in the population); (b) with her mother affected at age 40; (c) with her mother 
and sister unaffected at ages 70 and 50 respectively. No testing assumed in other family members, in 
all cases. 
 
Figure 2. BOADICEA Mutation Carrier Probabilities. BOADICEA mutation carrier probabilities for a 
female in the UK, born in 1975: (a) with unknown family history as a function of her breast cancer 
diagnosis age; (b) who was diagnosed with breast cancer at age 30 and whose mother was 
diagnosed with breast cancer, as a function of her mother’s age at diagnosis. 
 
Figure 3. BOADICEA Breast Cancer Risk for Negative Testing by Family History. The predicted risk of 
breast cancer for a 20 year old female in the UK, born in 1975 by her mother’s mutation status, for 
different family histories. The predicted risk is shown for four different family histories. The graphs 
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on the right hand side correspond to the pedigrees on the left hand side. The figures show the 
predicted risks for a proband (shown with an arrow)  in  families without any mutation testing in the 
five genes i.e. this corresponds to the predicted risk on the basis of family history information alone 
(grey curves). The rest of the curves correspond to the cases where the proband  is assumed to be 
negative for the mutation identified in the family. To enable direct comparisons, the proband is 
assumed to be 20 years old in all examples.   
 
